PANLAR 2021 Coverage

Inflammatory Myopathies, What Are They and What to Do?

By : Richard Aguirre
Periodista científico de Global Rheumatology by PANLAR.

12 August, 2021

"They are a group of diseases that cause inflammation of the muscles, although the causes are not yet known. "

Views 682Views


This is an open-access article distributed by the terms of the Creative Common Attribution License (CC-BY NC-4). The use, distribution or reproduction in other forms is permitted, provided the original author(a) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with this terms.

They are identified in three groups, their cause is unknown, although they have a name: inflammatory myopathies.

Among the groups that have identified these myopathies are polymyositis, which can affect children and adults; dermatomyositis, which also affects children and adults, but is characterized by the skin damage that sometimes predominates in the disease, and inclusion body myositis, which occurs mainly in adults aged 50 years and older.

These myopathies will also be protagonists in this version of the Congress and to discuss about the treatments and what, so far, the studies say, there will be two guests with careers dedicated to the research of this disease and the manifestations that have been identified.

One is Dr. Andrés Hormaza, from the Fundación Valle del Lili, Cali (Colombia), who will be in charge of the lecture on the specific antibodies of myositis.

He will also present on this group of diseases, which are classified within the autoimmune rheumatic diseases, and that through research conducted in recent years, several myositis "specific" antibodies have been discovered that allow and help to classify this group of diseases in a more appropriate way.

The second panelist, who will be at the end of the symposium, is Dr. Rohit Aggarwal, from the University of Pittsburgh, in the United States, and his lecture will focus on an update on the treatment of this group of inflammatory myositis, in which several new drugs have emerged that allow better results in the treatment of these patients.

Attendees will have firsthand what the evidence says about inflammatory myopathies and will have better inputs in an update symposium on these autoimmune diseases, which will allow, in addition to having a robust knowledge about them, access to keys and recommendations to diagnose and treat them. 


enviar Envía un artículo